FDA approves prostate cancer treatment

April 29, 2010 2:40:39 PM PDT
A new alternative for men with advanced stage prostate cancer has been approved by the FDA.The U.S. Food and Drug Administration has given approval to a therapeutic vaccine aimed at preventing the spread of prostate cancer.

It is called Provenge, and it will be used for men with an advanced form of the disease that is resistant to standard hormone therapy.

It appears to extend survival in men with advanced prostate cancer and does so without the serious side effects of chemotherapy, radiation and hormone therapy.

Provenge is a vaccine that is made from the patient's own white blood cells that are treated with the drug and placed back into the patient. That causes an immune response that kills cancer cells while leaving normal cells unharmed.